Targeting the immune system in intracerebral hemorrhage

JAMA Neurology

Volumn 71, Issue 9, 2014, Pages 1083-1084

  Sheth, Kevin N ^a   Rosand, Jonathan ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 17; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

APOPTOSIS; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; BRAIN ATROPHY; BRAIN EDEMA; BRAIN HEMORRHAGE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; UPREGULATION; ANALOGS AND DERIVATIVES; CEREBRAL HEMORRHAGE; FEMALE; MALE;

CEREBRAL HEMORRHAGE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84907532675     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1653     Document Type: Editorial

References (11)

1. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11(8):720-731.
2. Fu Y, Hao J, Zhang N, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study [published online July 7, 2014]. JAMA Neurol. doi:10.1001/jamaneurol.2014.1065.
3. Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain. 2005;128(pt 7):1622-1633.
4. Selim M, Yeatts S, Goldstein JN, et al Deferoxamine Mesylate in Intracerebral Hemorrhage Investigators. Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011;42(11):3067-3074.
5. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005;5(7):560-570.
6. Cohen JA, Barkhof F, Comi G, et al TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
7. Kappos L, Radue EW, O'Connor P, et al FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
8. Lu L, Barfejani AH, Qin T, Dong Q, Ayata C, Waeber C. Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage. Brain Res. 2014;1555:89-96.
9. Rolland WB, Lekic T, Krafft PR, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol. 2013;241:45-55.
10. Sheth KN, Kimberly WT, Elm JJ, et al. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014;45(1):281-283.
11. Kimberly WT, Battey TW, Pham L, et al. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014;20(2):193-201.